Stock AnalizArcus Biosciences, Inc. RCUS
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Arcus Biosciences, Inc. (RCUS) is a healthcare company listed in the US with a market value of about $2.5B. In the twelve months to September 30, 2026 it had revenue of $100M and net income of -$453M, a net margin of -453.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 26% a year, a 5-year average ROIC of -31%.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100M | $247M | $258M | $117M | $112M | $383M | $78M | $15M | $8M | $1M | — |
| Net income | -$453M | -$353M | -$283M | -$307M | -$267M | $53M | -$123M | -$85M | -$50M | -$53M | -$18M |
| Free cash flow | -$466M | -$484M | -$176M | -$330M | $432M | -$282M | $108M | -$75M | -$47M | -$31M | -$17M |
| EPS (diluted) | $-3.64 | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | $-1.43 | $-29.03 | $-20.80 |
| Net margin | -453.0% | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | — |
| ROIC | — | -46.6% | -40.5% | -46.1% | -28.2% | 5.5% | -18.8% | -42.7% | -18.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $41.00, 135% above the current price; targets range from $23.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $-3.48 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Arcus Biosciences pay a dividend?
Not currently.
Is Arcus Biosciences a good stock to buy?
We do not give buy or sell advice. Arcus Biosciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.